A panel of outside experts overwhelmingly recommended the Food and Drug Administration on Thursday clear a COVID-19 vaccine developed by Pfizer and BioNTech for emergency use, setting the stage for the potential rollout of the first such vaccine in the United States to start within days.
After a day-long discussion of clinical trial data, the advisory committee voted 17-4, with one abstention, for emergency use of the Pfizer-BioNTech vaccine, saying its benefits outweighed its risks in people 16 years old and older.
With the country surpassing 3,000 coronavirus deaths a day, the FDA is expected to act on the panel’s recommendation quickly, perhaps as early as Friday. If the agency accepts the panel’s advice, as it usually does, high-risk groups in Massachusetts — including health care workers and elderly residents of long-term care centers — could start rolling up their sleeves next week.
This breaking news story will be updated.
Jonathan Saltzman can be reached at email@example.com.